Opendata, web and dolomites

REGAIN SIGNED

REgeneration of inner ear hair cells with GAmma-secretase INhibitors to regain hearing in patients with sensorineural hearing loss

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "REGAIN" data sheet

The following table provides information about the project.

Coordinator
AUDION THERAPEUTICS BV 

Organization address
address: LINNAEUSPARKWEG 10-2
city: AMSTERDAM
postcode: 1098 EA
website: www.audiontherapeutics.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://yourhearing.eu
 Total cost 5˙834˙340 €
 EC max contribution 5˙834˙340 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AUDION THERAPEUTICS BV NL (AMSTERDAM) coordinator 1˙821˙330.00
2    Eli Lilly and Company Limited UK (Basingstoke) participant 1˙347˙362.00
3    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 1˙051˙188.00
4    NORDIC BIOSCIENCE CLINICAL DEVELOPMENT A/S DK (HERLEV) participant 715˙818.00
5    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) participant 331˙250.00
6    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 287˙466.00
7    UNIVERSITY COLLEGE LONDON HOSPITALSNHS FOUNDATION TRUST UK (LONDON) participant 153˙151.00
8    TTOPSTART BV NL (UTRECHT) participant 125˙000.00
9    ACCELOVANCE EUROPE BV NL ('S-HERTOGENBOSCH) participant 1˙771.00

Map

 Project objective

Hearing loss is a chronic non-communicable disease disabling over 328 million adults, and 32 million children worldwide. Sensorineural hearing loss due to loss of auditory hair cells was long thought to be irreversible. However, recent animal studies have demonstrated that pharmacological inhibition of cell signalling via Notch receptors using gamma-secretase inhibitors (GSIs) can regenerate hair cells and partially restore hearing capacity. This novel therapeutic concept provides the first promising lead for actual treatment of hearing loss. Clinical validation of these findings is the next crucial stepping stone in the development of a regenerative therapy for hearing loss. The ambition of REGAIN is to repurpose a GSI molecule for this indication by shifting from systemic to local treatment. The objective of the REGAIN project is to demonstrate and exploit the efficacy of locally administered GSIs to improve hearing through regeneration of inner ear hair cells with a lasting effect. The project will involve 1) the upscaling of GMP production of the clinical GSI candidate, 2) the generation of preclinical data on GSI dosing and local safety, 3) medical ethical clinical trial approval and 4) the demonstration of proof of concept for GSI for treatment of patients with recent onset sensorineural hearing loss. Small molecule drugs targeting the underlying biological causes of hearing loss in a safe way are expected to meet a real medical need for millions of patients, who currently rely on the limited benefits provided by hearing aids or cochlear implants. The partners involved in REGAIN represent the current state of the art in regenerative hearing loss research in the EU. REGAIN will break through that current state of the art, and will advance the first highly promising pharmaceutical treatment of hearing loss through clinical testing.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REGAIN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REGAIN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More